ARCHIVES

In Brief: Bruce Chamber Is DeVita’s Choice as Permanent Director Of DCT; Six New RCDAs Funded In FY 1982

This article is from The Cancer Letter archive.

Vol. 08 No. 24 | June 11, 1982

Download PDF Visit The Full Archive

Related Articles

ASCO Proposes Two IOM Workshops On Changing Clinical Trials Group System

September 17, 2010

I-ELCAP Results Internally Inconsistent, Peter Bach Writes

June 24, 2011

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

Cancer Letter Editor Wine Reporting Awards

June 11, 1999

NCAB Gives President Evidence Supporting Limits On Tar, Nicotine

November 29, 1974

In Congress: Societies, Advocates, Testify For Increases In Research Funding

February 13, 1998